Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04429971 · ClinicalTrials.gov registry record · NA
Pre-Exposure Prophylaxis in the Emergency Department
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT04429971 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 26 participants.
The verdict
NCT04429971, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
Despite an increasing armamentarium of behavioral and biomedical HIV prevention methods, since 2010 rates of new infection have remained around 40,000 annually. The demonstrated efficacy and subsequent approval of emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis (PrEP) for HIV by the FDA in 2012 was thought to represent a turning point that could significantly reduce the number of new infections. Since approval, the promise of PrEP as a transformative intervention has yet to be realized. Despite the implementation of systems for clinical evaluation for and initiation of PrEP by primary care providers, HIV specialists, and STI clinics, numerous barriers to PrEP expansion have been identified, including: 1) patient and provider lack of knowledge, 2) lack of access to medical care among high-risk individuals, 3) provider discomfort and inexperience with screening for risk behaviors, and 4) insurance and affordability. This proposal seeks to expand access to and engagement in PrEP among high risk individuals though an innovative delivery approach in the Emergency Department (ED) while addressing these four barriers.
Interventions
- OTHER PrEP screening program
- OTHER PrEP starter pack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-03-18 |
| Est. Completion | 2023-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04429971
The ClinicalTrials.gov registry entry for NCT04429971 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PrEP screening program is the first listed.
NCT04429971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04429971 about?
NCT04429971 is a clinical study titled "Pre-Exposure Prophylaxis in the Emergency Department". Despite an increasing armamentarium of behavioral and biomedical HIV prevention methods, since 2010 rates of new infection have remained around 40,000 annually. The demonstrated efficacy and subsequent approval of emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis (PrEP) for HI...
What is the current status of trial NCT04429971?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2020-03-18. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT04429971?
The interventions under investigation include: PrEP screening program (OTHER), PrEP starter pack (OTHER).
Who is sponsoring clinical trial NCT04429971?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.